Rosiglitazone
Composition
Contains Rosiglitazone, a thiazolidinedione (TZD) class antidiabetic agent that improves insulin sensitivity.
Indications
Used in the management of type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic drugs.
Side effects
Weight gain, edema, headache, increased risk of heart failure, possible liver enzyme elevation.
Precautions
Monitor for signs of heart failure; use with caution in hepatic impairment; assess cardiovascular risk before initiating therapy.
Contraindications
Heart failure (NYHA Class III/IV), active liver disease, type 1 diabetes, ketoacidosis.
Dosage and administration
Typical dose: 4–8 mg orally once daily or in divided doses.
Countries
Exported to Mexico
Available Forms
Oral tablets (usually 2 mg, 4 mg, 8 mg).